GENE ONLINE|News &
Opinion
Blog

Clash of three migraines medications & cost benefit for patients

by GeneOnline
Share To

By Ajay V. Patil

With the eligible patient pool of about 15 million, three migraine medications – Aimovig (Amgen), Ajovy (Teva), Emgality (Eli Lilly) fight for the market share with similar medical plans

Within short period of last 5 months, FDA approved three preventive drugs for alleviating migraines. This is very important considering the patient pool of about 36 million around the world, among which 15 million patients are expected to be eligible for these treatments. Before this, the commonly used treatments like botox and anti-seizure medications, pain relievers were used, just to treat some of the symptoms of migraines.

Here are those three approved medications,

  1. Aimovig (Erenumab) from Amgen and Novartis is a fully human monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRP-R) with 70 mg–140 mg once a month recommended dosage.
  2. Ajovy (Fremanezumab) from Teva is also a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), with two dosing options – 225 mg (monthly), or 675 mg (quarterly).
  3. Emgality (Galcanezumab) from Eli Lilly is another humanized monoclonal antibody directed against CGRP with the dosage of 120 mg once a month.

All these products have $575 per month list price and patient assistance programs which could provide up to a year of free coverage for patients. The free coverage for a year is planned, keeping in mind the chronic nature and wider epidemiology of the disease. The expectation by the companies is that, patients will be on the medication enough time to make up for initial investment. This is not the first time that similar products employ such cost saving strategies to capture the market. We have recently seen the similar strategy being employed with 50% price cuts offered by both Keytruda and Opdivo in the Chinese market. Looking at the current scenario, prices of these preventive drugs for migraine are expected to be even more affordable from the next year.

Besides these three drugs, another similar candidate eptinezumab from Alder Biopharmaceuticals is also under development. Ultimately the drug with superior long standing performance will have a better market share.

References

  1. https://www.businessinsider.com/prices-for-new-migraine-treatments-for-2018-2018-9
  2. https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention
  3. https://marketrealist.com/2018/09/competition-dynamics-for-ajovy-tevas-migraine-drug

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Aug 28-Sept 1
2023-09-05
GeneOnline’s Weekly News Highlights: Aug 21-25
2023-08-28
R&D
Introducing Veopoz™: A Breakthrough Treatment for CHAPLE Disease
2023-08-28
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top